Medical association
Appears in 1 story
Hosted the annual meeting where olatorepatide data were presented
Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
